Tomra Systems ASA (OSL:TOM)

Table of Contents

• Executive Summary
• 1. The Backbone of the Play
• 2. Business Model — Real Detail
• 3. Sector Deep-Dive
  • 3a. Competitor "Better Buy" Check
• 4. Multi-Quarter Financial Trajectory
  • 4a. Prior Brief Reconciliation
• 5. Forward Guidance & Consensus
  • 5a. Insider Activity & Ownership
• 6. Valuation — Multiple Lenses + Independent Fair Value
  • 6a. Market Multiples
  • 6b. Independent Fair Value Assessment
• 7. Headwinds & Tailwinds — Separated
• 8. Macro & Sector Context
• 9. Risks & Red Flags — Detailed Register
  • 9a. Retail Sentiment
• 10. Technical State
• 11. Verdict
• 12. Notes & Caveats

Executive Summary

Bottom line: Q2 2026 showed the regulatory pipeline converting into revenue (+25% YoY to a record €405M), but new-market equipment mix pulled Collection gross margin down to 38.6%, Q2 free cash flow was about €10M, net debt/EBITDA is 2.5x, and the credit rating was cut to BBB+. The valuation has two earnings bases that give different answers: on this brief's FY2027E EPS of NOK 4.73 the 12-month base is NOK 113.5, while on FY2026E EPS of NOK 2.95 the intrinsic-today base is NOK 70.8, because interest and amortisation absorb about 40% of FY2026 EBITA. The 12-month case needs the UK delivery year to land on schedule. The view turns on whether Collection gross margin clears 40% in H2 2026, whether leverage stays below 3.0x, and whether the shares hold 89.80 into the Q3 report on 23 October.

1. The Backbone of the Play

Tomra is the dominant supplier of deposit-return reverse vending machines and a leading sensor-based sorting vendor. The thesis rests on legislated deposit-return roll-outs and EU packaging regulation creating a captive equipment market, with an industry-estimated 70–80% share of installed RVMs (not stated in company filings).

• Q2 2026: revenue +25% YoY to €405M; Collection +45% to €246M (new-market €69M vs €15M); adjusted EBITA +30% to €57M (14.1% margin).
• UK: company releases announce ~2,700 RVMs under a letter of intent plus ~1,200 appointed, about 3,900 in total against an estimated ~25,000-unit initial market; a letter of intent is not a firm order, and deliveries are guided from Q4 2026 with the bulk in 2027.
• Margin dilution: Collection gross margin 38.6% (41.8% a year earlier); group gross margin 41.3%, down 3 points YoY. Recycling revenue -11% but order intake +40% to €58M; Food order intake -22%.
• Leverage: net interest-bearing debt/EBITDA 2.46x vs 1.8x a year earlier after debt-funded Clynk and Collection Australia deals; Scope Ratings cut the rating from A- to BBB+.

Strongest dissent: Collection's 45% growth may be a low-margin equipment supercycle that repeats with the UK volume, while 2.46x leverage leaves less room for margin pressure or working-capital drag. This case wins if Collection gross margin stays below 40% for two consecutive quarters or net debt/EBITDA breaches 3.0x before UK working capital unwinds.

2. Business Model — Real Detail

Tomra sells and leases RVMs and sorting equipment, then earns recurring service and throughput fees in Collection.

• Collection (~62% of Q1 revenue): RVM hardware plus throughput and service fees (~40% of divisional revenue, higher margin). New-market phases are equipment-heavy and dilute margin.
• Recycling (~11%): sensor-based sorting; most cyclical division; €16M restructuring programme with full effect from 2027.
• Food (~24%): optical sorting; record backlog of €136M at end-2025, €121M at end-Q2 2026.
• Horizon (~3%): loss-making incubation (Feedstock, Reuse, c-trace); capex ~€10M in 2026 vs €24M in 2025.
• Moat: installed-base scale and service reliability; schemes certify more than one supplier, so switching costs at scheme level are moderate.
• Customers: retail chains, beverage producers and scheme operators (Germany, Norway, Sweden, Netherlands, Australia); Recycling and Food sell to industrial operators.
• FX: about 50% of group income is non-EUR; a 10% EUR move changes EBITA about 5%; +1pp in rates adds about €4M of annual financial expense.

3. Sector Deep-Dive

Moat summary: Tomra has the largest RVM installed base (~91,900 Collection installations per the company) and the only listed at-scale RVM franchise. Third-party evidence points to moderate, not high, lock-in: Romania's scheme admits any self-certified RVM provider, and UK retailers are already splitting supply between Tomra and Envipco. Sorting barriers are lower than in RVMs.

Top competitors:

• Envipco (AMS/OSL:ENVI): challenger with a final ~1,500-unit Iceland Foods UK contract; Q2 2026 gross margin 32.2%, EBITDA -€1.7M; on the Oslo Børs penalty bench and CEO left 30 April 2026.
• RVM Systems (Sweden, private): described as second-largest by installed base; entering Germany via acquired RE DEPOSIT assets.
• Bühler, Steinert, Pellenc ST, Key Technology: private or subsidiary sorting alternatives in Recycling and Food.

3a. Competitor "Better Buy" Check

Conclusion: None identified. Envipco, the only listed like-for-like peer, is loss-making with estimates cut to a forecast loss; Repant is sub-scale and the sorting rivals are private.

4. Multi-Quarter Financial Trajectory

• Revenue growth has accelerated two quarters running (+9.2%, +24.6%) and EBITDA recovered from €37M in Q1 to €81M in Q2, but reported EBIT margin swung from 1.5% to 12.1%, showing how thin reported operating profit remains.
• Cash conversion lags: Q2 FCF about €10M against about €35M in Q1 as working capital absorbs cash (19% of revenue); leverage is 2.46x vs 1.8x a year earlier.

4a. Prior Brief Reconciliation

One cell differs from the 2026-08-05 brief by more than 10%: Q2 2026 FCF moves from ~€14M to ~€10M (about -29%), because the cash-flow statement's total investing outflow of €28M includes a €4M subsidiary/associate purchase the earlier figure excluded. All other headline cells are unchanged.

5. Forward Guidance & Consensus

Guidance issued with Q2 2026 results (17 July 2026), unchanged since:

• Collection: H2 revenue €400–440M; FY2026 gross margin ~40% (above 40% in H2); H2 quarterly opex ~€52M; UK early installations late 2026, bulk in 2027.
• Recycling: FY revenue €200–215M; ~50% of the €105M backlog converts in Q3 at 45–50% gross margin.
• Food: FY revenue €340–360M; ~65% of the €121M backlog converts in Q3; H2 gross margin 43–47%.
• Horizon / Group: Horizon revenue €45–50M; group capex €90–100M; ~15% of revenue is US sales, over 90% imported from the EU.
• Implied FY2026 group revenue: about €1,439–1,519M (+9–15% YoY). 2030 targets include an 18% group EBITA margin.
• Consensus: TOMRA's IR compilation (31 Jul, 9 contributors) shows FY26E adj. EPS €0.32 and FY27E €0.66, with no price target; 13 brokers cover the stock. Aggregator price targets are undated and not used.

5a. Insider Activity & Ownership

Net buyer: eight open-market purchases by six board members between November 2025 and 30 July 2026 (NOK 95.82–138.48, about NOK 3.31M in total), with no disclosed sales; a May 2026 employee share programme purchase by seven executives is a separate, lower-signal item. Investment AB Latour holds about 21.1%.

6. Valuation — Multiple Lenses + Independent Fair Value

Basis: price NOK 92.95, 295.70M shares, EUR/NOK 10.935; net debt €640M (30 Jun 2026); EV NOK 34.49B.

6a. Market Multiples (context)

Peer median forward P/E is 16.7x and EV/EBITDA 10.7x. On consensus FY27E TOMRA screens below the peer median; on this brief's own FY27E it screens above it. The gap between the two EPS bases, not the multiple, is what the valuation turns on. Price/book is 4.4x.

6b. Independent Fair Value & Forward Price Targets

Multiple range used (anchored): Bear 17× (peer median 16.7x) · Base 24× (peer 75th percentile 24.3x; about two-thirds of own 2024–25 trailing ~38x) · Bull 30×. Growth gate: decelerating into H2 (Collection H2 revenue guided €400–440M vs €454M in H1), so the base multiple was set at 24x against 26x on 5 Aug 2026.

Synthesis Matrix (HEADLINE)

Current price NOK 92.95 → vs 12M PT base: 113.5 is +22.1% above the price · vs Intrinsic base: 70.8 is 23.8% below the price (the price is 31.3% above it).

12-Month Price Target (primary horizon)

EPS basis vs the IR consensus. The own FY27E (€0.433) differs from the IR consensus (€0.66) by about 50%. The consensus needs adj. EBITA of €313M (17.3% margin) one year after a FY26 guided at ~12%, near the 2030 target of 18%. The own build assumes revenue €1,685M (+14%), adj. EBITA €248M (14.7%) and €72M of below-EBITA costs (amortisation plus net finance), giving adj. net profit €128M.

Current Intrinsic Fair Value (today)

The FY26E build takes each guided range at its midpoint: H2 adj. EBITA ~€97M, FY26E ~€180M (12.2%; IR consensus €189M), after ~€36M of H2 below-EBITA costs, for adj. EPS €0.27 = NOK 2.95.

EV/EBITDA cross-check: corroborates the Fwd P/E build at 12 months (NOK 116.3 vs 113.5), though it is anchored at the peer median while the P/E base sits at the peer 75th percentile, so the agreement is partly a product of that choice, and contradicts it at the intrinsic horizon (NOK 87.0 vs 70.8, +23%).

Revenue-growth-implied check: the price needs ~4.7% revenue CAGR to FY29E at a 15% margin against ~8% achievable, so it reads undervalued at 15% and fair at a 13% terminal margin; the result is margin-sensitive.

Triangulation & Verdict

• vs 12M PT base (113.5): undervalued by ~18%. The price is 18.1% below the base, which sits 22.1% above the price. The forward P/E and EV/EBITDA agree within 3% (on different peer-percentile anchors), and the revenue-growth check reads undervalued at a 15% terminal margin.
• vs Intrinsic base (70.8): overvalued by ~31%. The price sits 31.3% above the base. EV/EBITDA puts intrinsic at 87.0, which still leaves the price ~7% rich.

The stock is priced above what FY26 trough earnings support today, and below what a UK-driven FY27 supports. The 12-month case needs FY27 delivery: a UK slip into FY28 would push the 4.73 NOK basis back a year.

Where the two fair values split. The EPS basis and the multiple each contribute. Against the 5 Aug 2026 assessment, the intrinsic base moves from 106 to 70.8: about 83% is the earnings basis (FY26E NOK 4.06 → 2.95, because H1 accounts run at ~€72M annualised below-EBITA costs against ~€44M in FY2025) and about 17% the multiple trim (26x → 24x). The 12M base moves from 142 to 113.5: about 66% is the FY27E basis (NOK 5.45 → 4.73) and about 33% the multiple. No new operating data has been filed since 17 July. The P/E and EV/EBITDA methods diverge today (70.8 vs 87.0) because below-EBITA costs absorb ~40% of FY2026 EBITA, and converge by FY27 (113.5 vs 116.3); the today-verdict therefore carries lower conviction than the 12-month one.

[Trough-Recovery Pricing] The intrinsic base assumes H2 2026 adj. EBITA of ~€97M, a 13.1% margin, up from 11.2% in H1. That rests on Collection gross margin clearing the guided >40% in H2, which H1 has not shown (Q2 38.6%), and on Recycling converting ~50% of its €105M backlog in Q3. At NOK 92.95 the price is 31% above that intrinsic base, so the market is pricing both the H2 recovery and the FY27 UK year with no margin for timing risk. If delivery slips by 1–2 quarters, the stock is unlikely to hold this level even if the thesis remains intact.

7. Headwinds & Tailwinds — Separated

Tailwinds

1. Poland and Portugal roll-outs: Q2 revenue +25% YoY; new-market Collection €69M vs €15M, slowing in H2 per guidance.
2. UK DRS orders: ~3,900 RVMs under LOI or appointment; deliveries from late 2026, bulk in 2027.
3. Recycling order intake +40% YoY in Q2 (leading indicator, not a confirmed bottom).
4. Cost programme: €16M Recycling restructuring at full effect from 2027; Horizon capex falling to ~€10M.

Headwinds

1. Collection gross margin 38.6% vs 41.8% on equipment-heavy new-market mix; guide ~40% for FY2026.
2. Leverage 2.46x vs 1.8x; Scope cut Tomra to BBB+ on 3 Jun 2026.
3. Cash conversion: Q2 FCF about €10M vs about €35M in Q1.
4. Back-half-weighted plan: the guidance-midpoint build needs H2 adj. EBITA margin of about 13.1% against about 11.2% in H1.

8. Macro & Sector Context

• Sector posture and flows: weakening, with outflow signals: TOM is -15.3% over 30 days, price is below the 20/50/200-day averages, OBV 20-day slope is -4.74M and only 39.6% of US stocks sit above their 200-day average. No Oslo industrials index series was gathered.
• Rates: Fed 3.75–4.00%, ECB 2.50% and BoJ 1.25% all tightened within a month; US 10Y 5.245%. Tomra adds about €4M of annual financial expense per +1pp on €640M of net debt.
• FX and calendar: EUR/NOK 10.935; about 50% of income is non-EUR (10% EUR move ≈ 5% of EBITA). Tomra Q3 report 23 Oct; FOMC 27–28 Oct; Capital Markets Day 2026 date not located.

9. Risks & Red Flags — Detailed Register

1. Valuation: trailing P/E 31.3x and EV/EBITDA 12.0x; the FY26 earnings base depends on the H2 recovery, and a break of the 89.8 low opens the gap to the 84.93 lower Bollinger band.
2. Balance-sheet quality: goodwill €369M is a key audit matter, about 64% of shareholders' equity (€573M).
3. Leverage, rating, covenant: 2.5x net debt/EBITDA, BBB+, Q2 FCF about €10M against a €59M dividend; 30% equity covenant with headroom not disclosed.
4. UK timing and competition: ~75% of the estimated 25,000-unit UK market is not announced to either supplier; Greece postponed, Spain TBD; Envipco holds ~2,300 UK units.
5. Trade / FX: about 15% of revenue is US sales (over 90% imported from the EU); about 50% of income is non-EUR.

9a. Retail Sentiment

Not produced: no retail-sentiment source of adequate reliability was found.

10. Technical State

The July recovery failed: price is 92.95, down 15.4% since the prior read, and the prior supports at 105.99, 101.54 and 98.44 were lost. The 50-day sits below the 200-day (death cross active). Oscillators show a first relief turn, but volume-based indicators show distribution.

Short interest: 3.5% of issued capital (17 Sep), up from 2.89% on 30 Jul; too low for a squeeze setup.

11. Verdict

Fair-value perspective: At NOK 92.95 the price sits between the two §6 anchors. It is 18.1% below the 12-month base of NOK 113.5 (FY27E EPS NOK 4.73 at 24x), which needs the UK delivery year to land in FY2027, Collection to hold its H1 2026 ~17% EBITA margin and Recycling to recover on the +40% Q2 order intake. It is 31.3% above the intrinsic-today base of NOK 70.8 (FY26E EPS NOK 2.95 at 24x), because interest and amortisation absorb about 40% of FY2026 EBITA. The EV/EBITDA cross-check agrees with the P/E on the 12-month horizon (NOK 116.3 against 113.5, though on a peer-median anchor against the P/E's 75th-percentile base) but puts today's value at NOK 87.0, so the today-verdict carries lower conviction than the 12-month one. The bull case of NOK 141.9 needs the 30x multiple on the same FY27E earnings; the bear case of NOK 80.4 is 17x (the peer median) on the same basis and sits 13.5% below the price. An Acceleration case of NOK 178.5 would need the full UK bulk order to be recognised in FY2027 with no slip into FY2028, and Collection to hold ~17% EBITA margin through the volume peak; the growth gate did not find evidenced acceleration, so it is shown as optional.

The fair-value change against the 5 Aug 2026 assessment is mostly a change of earnings basis rather than of operating outlook. The intrinsic base moves from NOK 106 to NOK 70.8: about 83% of the cut comes from the EPS basis (the earlier FY26E EPS of about NOK 4.06 assumed below-EBITA costs of about €44M a year, while the H1 2026 filed accounts run at about €72M a year) and the rest from a multiple trim from 26x to 24x. The 12-month base moves from NOK 142 to NOK 113.5: about 66% of the cut comes from the same EPS basis and the rest from the multiple trim. No new operating data has been filed since the 17 July report.

[Trough-Recovery Pricing] The intrinsic base assumes H2 2026 adj. EBITA of ~€97M, a 13.1% margin, up from 11.2% in H1. That rests on Collection gross margin clearing the guided >40% in H2, which H1 has not shown (Q2 38.6%), and on Recycling converting ~50% of its €105M backlog in Q3. At NOK 92.95 the price is 31% above that intrinsic base, so the market is pricing both the H2 recovery and the FY27 UK year with no margin for timing risk. If delivery slips by 1–2 quarters, the stock is unlikely to hold this level even if the thesis remains intact.

Thesis-invalidation rationale: Technically, a daily close below NOK 89.80, the 52-week low, would break the last structural floor after every higher support (105.19, 101.99 and the earlier 98.44 level) has been lost; the lower Bollinger band at 84.93 is the nearest measured reference below it and no earlier price history in the window defines support there. Fundamentally, the thesis rests on Collection's new-market equipment mix maturing into higher-margin throughput revenue and on leverage stabilising: if Collection gross margin fails to clear the >40% full-year 2026 guidance for two or more consecutive quarters after the Poland/Portugal/Singapore/Romania install wave crests, or if net debt/EBITDA (2.5x at Q2, not yet close to the 3.0x trigger) breaches 3.0x before UK working capital unwinds, the "low-margin equipment supercycle" bear case in §1 would be validated over the throughput-fee compounding case.

Catalysts to watch:

1. TOMRA Q3 2026 interim report — 23 October 2026 (issuer-filed date). First hard test of Collection gross margin against the >40% H2 guide, Q3 conversion of ~50% of the €105M Recycling backlog and ~65% of the €121M Food backlog, and leverage against 2.5x.
2. Capital Markets Day 2026. The invitation was published on 24 August; the date was not located in the sources checked, so the timing and any target update are unconfirmed.
3. UK RVM deliveries beginning — guided from late 2026, with the bulk in 2027. Delivery on schedule without slippage to FY2028 is the largest lever on the 12-month case.
4. Short-interest disclosures. Disclosed short interest is 3.5% and rising; a reversal in the Finanstilsynet register would be an early positioning signal.
5. Next IR consensus update — about a week before the Q3 report. The first dated read on whether estimates have moved since 31 July.

Invalidation conditions:

1. Collection gross margin fails to clear the >40% full-year 2026 guidance for two or more consecutive quarters after the install wave crests.
2. Net interest-bearing debt/EBITDA breaches 3.0x before UK working capital unwinds (guided 2027-2028).
3. UK DRS deliveries slip beyond 2027 into FY2028.
4. The Recycling order-intake reversal (+40% YoY in Q2 2026) fails to convert into backlog growth.
5. Free cash flow fails to recover from the Q2 2026 level of about €10M, further compressing coverage of the NOK 2.15 per share dividend (€59M paid in Q2).

Positioning & momentum context: Disclosed short interest is 3.5% of issued capital and rising (2.89% on 30 July), the price sits 3.5% above the 52-week low of 89.80 and below the 20-, 50- and 200-day averages, and OBV and the A/D line both confirm distribution. The lean is toward continued pressure and a test of 89.80 while price stays under the 20-day SMA at 95.19, with a relief bounce the better-supported alternative only if the Stochastic and MACD turn is joined by rising volume-based indicators and a reclaim of 101.99. With a float of 217.57M shares and 3.5% short, short interest is too low for a squeeze setup; covering would be a modest upside catalyst only on a sustained move above 101.99 or a constructive Q3 report. This context is informational; the fundamental verdict above reflects the medium-to-long-term thesis and is not a near-term momentum read.

Competitor note: Section 3a identified no listed competitor offering a materially better fair-value setup. Envipco's Q2 2026 EBITDA was -€1.7M, its H1 operating loss widened to €8.2M and analysts moved to a forecast loss; it has been placed on the Oslo Børs penalty bench for late reports and its CEO left on 30 April 2026. Repant is sub-scale; Bühler, Steinert and Pellenc ST are private. TOM is the primary listed vehicle for this thematic exposure.

What would increase conviction:

1. Collection gross margin re-crossing 40% in H2 2026 as guided.
2. A reclaim of the 50-day SMA (101.99) with rising OBV and A/D slopes.
3. UK RVM deliveries beginning on the guided late-2026 schedule without slippage.
4. Net debt/EBITDA stabilising or declining from 2.5x, and free cash flow recovering above €10M a quarter.
5. Dated broker estimate revisions moving toward the FY27E earnings basis used here.
6. Further open-market board purchases extending the two 2025–26 buying clusters in §5a, with no insider selling.

What would decrease conviction:

1. A daily close below NOK 89.80 (52-week low).
2. Collection gross margin still below 40% after two more quarters.
3. A further leverage increase or a second ratings downgrade.
4. UK delivery slippage into FY2028.
5. Disclosed short interest continuing to rise while price falls.

12. Notes & Caveats

• Refresh: this brief was refreshed from the 2026-08-05 brief; no new quarterly result has been filed since 17 July 2026.
• Audit-corrected cells (6): Q2 2024 Op Margin (~12.3% → 11.7%); Q3 2024 Op Margin (~12.3% → 12.0%); FY 2023 Net Income (€64M → €59M majority-attributable); FY 2023 EBITDA (€119M → €198M); FY 2025 FCF (€39M → €42M); Q2 2026 FCF (€14M → ~€10M).
• Data flags: the Q1–Q3 2024 and Q1 2025 FCF cells match operating cash flow rather than a capex-net figure; do not use them for a quarter-by-quarter FCF trend. No dated all-broker price target was found; UK unit counts rest on company releases.
• Correction (30 Sep 2026): the bear multiple was re-anchored from 18x to the peer median (17x), moving the bear cases to NOK 80.4 (12-month) and NOK 50.2 (intrinsic today); the 12-month and intrinsic base and bull are unchanged. The 6-month target is now a fixed 50/50 blend of FY26E and FY27E EPS (NOK 3.84): Bear NOK 65.3 · Base NOK 92.2 · Bull NOK 115.2 (from 85.1 / 113.5 / 141.9). The headline forward P/E is now on this brief's own FY27E EPS (19.7x, not the consensus 12.9x); goodwill is about 64% of shareholders' equity (from 58%); the FCF column now labels the operating-cash-flow quarters.
• Confidence: Medium. The main constraints are the gap between the own FY27E EPS (€0.433) and the IR consensus (€0.66), the P/E and EV/EBITDA methods disagreeing on today's value (NOK 70.8 against 87.0), and the technical downtrend ahead of the 23 October report.